Clinical trials of biosimilars should become more similar.

Item

http://www.wikidata.org/entity/Q48092147

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Clinical trials of biosimilars should become more similar.

@en

Clinical trials of biosimilars should become more similar.

@nl

type

Item

label

Clinical trials of biosimilars should become more similar.

@en

Clinical trials of biosimilars should become more similar.

@nl

prefLabel

Clinical trials of biosimilars should become more similar.

@en

Clinical trials of biosimilars should become more similar.

@nl

P1476

Clinical trials of biosimilars should become more similar.

@en

P2860

The changing landscape of biosimilars in rheumatology

A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.

A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects.

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.

A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.

Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci et al.

A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.

P304

4-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1136/ANNRHEUMDIS-2015-208113

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jonathan Kay

John D Isaacs

P577

2016-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27566795

http://www.w3.org/2001/XMLSchema#string